Revenue expanded to $359.5M in 2026Q3 with operating margin turning positive at 13.0%, but gross margin compressed from 73.0% in 2024Q2 to 58.9%, suggesting rising per-patient costs may be absorbing part of the top-line gains.
Legend Biotech Corporation (LEGN) annual income statement — 9-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Sales/Revenue | 1.36B | 1.03B | 627.24M | 285.14M | 117M | 68.83M | 75M | 61.8M | 49.13M | 23.59M |
| Revenue Growth % | 49.45% | 64.04% | 119.97% | 143.7% | 70% | -8.23% | 21.36% | 25.78% | 108.24% | - |
| Cost of Goods Sold | 584.36M | 408.1M | 234.58M | 144.21M | 65.36M | 0 | 0 | 0 | 0 | -96K |
| COGS % of Revenue | - | 39.66% | 37.4% | 50.58% | 55.86% | - | - | - | - | -0.41% |
| Gross Profit | 774.12M | 620.8M | 392.66M | 140.93M | 51.64M | 68.83M | 75M | 61.8M | 49.13M | 23.69M |
| Gross Margin % | 56.98% | 60.34% | 62.6% | 49.42% | 44.14% | 100% | 100% | 100% | 100% | 100.41% |
| Gross Profit Growth % | - | 58.1% | 178.62% | 172.9% | -24.97% | -8.23% | 21.36% | 25.78% | 107.4% | - |
| Operating Expenses | 740.02M | 757.3M | 695.9M | 580.41M | 507.26M | 461.11M | 75M | 194.31M | 64.2M | 9.6M |
| OpEx % of Revenue | - | 73.6% | 110.95% | 203.55% | 433.54% | 669.97% | 100% | 314.42% | 130.68% | 40.67% |
| Selling, General & Admin | 357.49M | 341.6M | 284.26M | 200.93M | 174.05M | 149.5M | 72.7M | 32.37M | 3.93M | 1.4M |
| SG&A % of Revenue | - | 33.2% | 45.32% | 70.47% | 148.75% | 217.22% | 96.94% | 52.38% | 8% | 5.94% |
| Research & Development | 378.58M | 414.7M | 413.54M | 382.22M | 335.65M | 313.35M | 232.16M | 161.94M | 60.64M | 8.2M |
| R&D % of Revenue | - | 40.31% | 65.93% | 134.04% | 286.87% | 455.27% | 309.55% | 262.04% | 123.41% | 34.73% |
| Other Operating Expenses | 2M | 1M | -1.91M | -2.73M | -2.43M | -1.74M | -229.87M | 0 | -2K | 0 |
| Operating Income | 34.1M | -136.5M | -303.24M | -439.49M | -455.62M | -392.29M | 0 | -132.51M | -1.53M | 13.78M |
| Operating Margin % | 2.51% | -13.27% | -48.35% | -154.13% | -389.4% | -569.97% | - | -214.42% | -3.12% | 58.41% |
| Operating Income Growth % | - | 54.99% | 31% | 3.54% | -16.14% | - | 100% | -8538.46% | -111.13% | - |
| EBITDA | 84.37M | -107.6M | -279.88M | -419.03M | -437.23M | -378.37M | -298.16M | -127.25M | 149K | 14M |
| EBITDA Margin % | 6.21% | -10.46% | -44.62% | -146.96% | -373.68% | -549.75% | -397.54% | -205.91% | 0.3% | 59.33% |
| EBITDA Growth % | 150.63% | 61.56% | 33.21% | 4.16% | -15.56% | -26.9% | -134.3% | -85504.03% | -98.94% | - |
| D&A (Non-Cash Add-back) | 50.27M | 28.9M | 23.36M | 20.45M | 18.39M | 13.92M | 9.93M | 5.26M | 1.68M | 217K |
| EBIT | 49.28M | -261.2M | -136.52M | -498.32M | -434.93M | -406.3M | -308.09M | -132.51M | -1.53M | 13.84M |
| Net Interest Income | 8.47M | 18.7M | 39.59M | 32.69M | -2.61M | 71K | -1.28M | 4.36M | 6.13M | 0 |
| Interest Income | 23.55M | 40.1M | 61.2M | 54.49M | 8.18M | 971K | 2.93M | 4.58M | 6.21M | 1K |
| Interest Expense | 15.08M | 21.4M | 21.61M | 21.79M | 10.8M | 900K | 4.21M | 223K | 82K | 0 |
| Other Income/Expense | -1.9M | -146.1M | 145.11M | -80.63M | 9.9M | -14.91M | -308.29M | 5.2M | 13.46M | -40K |
| Pretax Income | 32.2M | -282.6M | -158.13M | -520.12M | -445.72M | -407.2M | -308.29M | -127.32M | -1.62M | 13.84M |
| Pretax Margin % | 2.37% | -27.47% | -25.21% | -182.41% | -380.94% | -591.63% | -411.05% | -206.02% | -3.29% | 58.65% |
| Income Tax | 32.42M | 14.2M | 18.89M | -1.86M | 625K | -3.61M | -41.91M | -25.73M | 1.17M | 4.47M |
| Effective Tax Rate % | 100.67% | -5.02% | -11.95% | 0.36% | -0.14% | 0.89% | 13.6% | 20.21% | -72.28% | 32.32% |
| Net Income | -215K | -296.8M | -177.03M | -518.25M | -446.35M | -403.58M | -266.37M | -101.59M | -2.78M | 9.37M |
| Net Margin % | -0.02% | -28.85% | -28.22% | -181.75% | -381.48% | -586.38% | -355.16% | -164.39% | -5.67% | 39.69% |
| Net Income Growth % | 99.91% | -67.66% | 65.84% | -16.11% | -10.6% | -51.51% | -162.2% | -3549.07% | -129.73% | - |
| Net Income (Continuing) | -215K | -296.8M | -177.03M | -518.25M | -446.35M | -403.58M | -266.37M | -101.59M | -2.78M | 9.37M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -1.60 | -0.97 | -2.94 | -2.81 | -2.74 | -2.57 | -1.01 | -0.03 | 0.07 |
| EPS Growth % | 97.71% | -64.95% | 67.01% | -4.63% | -2.55% | -6.61% | -154.46% | -3533.09% | -139.21% | - |
| EPS (Basic) | - | -1.60 | -0.97 | -2.94 | -2.81 | -2.74 | -2.57 | -1.01 | -0.03 | 0.07 |
| Diluted Shares Outstanding | 193.8M | 184.32M | 182.85M | 176.08M | 159.04M | 140.85M | 118.15M | 132.01M | 100.21M | 132.01M |
| Basic Shares Outstanding | 187M | 184.32M | 182.85M | 176.08M | 159.04M | 140.85M | 118.15M | 132.01M | 100M | 132.01M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LEGN stock.
For fiscal year 2025, Legend Biotech Corporation (LEGN) reported total revenue of $1.03B. This represents a 4260.9% increase compared to $23.6M in 2017.
Legend Biotech Corporation (LEGN) reported a net loss of $296.8M for the fiscal year ending 2025.
Legend Biotech Corporation (LEGN) reported an operating income of $-136.5M, resulting in an operating profit margin of -13.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Legend Biotech Corporation (LEGN) generated $620.8M in gross profit for the year, representing a gross profit margin of 60.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses despite growth
Revenue Growth Driven by Carvykti Expansion
Based on reported quarterly figures, LEGN's revenue rose from $160.2M in 2024Q3 to $359.5M in 2026Q3, a year-over-year growth rate of roughly 32% to 70% across recent quarters that suggests the commercial launch is gaining meaningful momentum.
The reported growth trajectory appears driven primarily by expanding Carvykti patient volumes and label expansion into earlier lines of therapy, though the lumpy quarterly pattern suggests milestone timing may be contributing to period-to-period swings. Investors should monitor whether growth remains durable once milestone recognitions normalize, since the sequential decline from $387.5M in 2026Q2 to $359.5M in 2026Q3 may indicate volatility rather than a sustained trend.
Gross Margin Compressed Below Earlier Peaks
According to reported income statements, LEGN's gross margin fell from 73.0% in 2024Q2 to 58.9% in 2026Q3, a decline that may reflect rising per-patient manufacturing and logistics costs as volumes scale.
The compression suggests the individualized autologous manufacturing process carries cost characteristics that do not scale as favorably as small-molecule or software-like economics. Whether margins stabilize near current levels or recover will likely depend on manufacturing efficiency gains, and investors should monitor whether the 2026Q1 trough of 42.3% represents an anomaly or an emerging structural pattern.
Operating Losses Persist Despite Revenue Scale
Based on reported figures, LEGN's operating margin moved from -43.7% in 2024Q3 to a positive 13.0% in 2026Q3, indicating that operating leverage has begun to emerge after several quarters of sustained losses.
The shift to positive operating income in recent quarters suggests that R&D and SG&A spend, while still substantial at roughly $95M and $70M respectively, is being absorbed more efficiently against a growing revenue base. However, the negative operating result in 2026Q1 indicates the improvement has not been linear, so investors should treat the recent positive quarters as early evidence warranting further confirmation.
Net Income Diverges from Operating Results
As reported in financial statements, LEGN's net income swung from -$125.4M in 2025Q2 to $51.7M in 2026Q3, a divergence from operating results that may reflect non-operating items or partnership accounting effects.
The gap between operating income and net income in several quarters suggests non-operating items, tax effects, or collaboration accounting adjustments are materially influencing reported earnings. Given the 50/50 profit-sharing structure with Janssen, analysts should examine whether reported net income reflects distributable economics or accounting timing, and treat EPS figures with caution until this is clarified.
Growth Quality and Cash Burn Risks
Based on reported quarterly data, LEGN recorded net losses in most of the last ten quarters, and the absence of formal guidance in recent reports may limit visibility into whether operating leverage is durable.
A bear case would emphasize that revenue growth is concentrated in a single asset, that gross margins have compressed meaningfully, and that milestone-driven revenue can obscure underlying commercial demand. Investors should monitor whether the recent positive operating quarters persist, as a reversal would suggest the earnings inflection may be less durable than headline growth implies.